Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort

Abstract

AIMTo compare the performances of the Barcelona clinic liver cancer (BCLC) nomogram and others systems (BCLC, HKLC, CLIP, NIACE) for survival prediction in a large hepatocellular carcinoma (HCC) French cohort.METHODSData were collected retrospectively from 01/2007 to 12/2013 in five French centers. Newly diagnosed HCC patients were analyzed. The discriminatory ability, homogeneity ability, prognostic stratification ability Akaike information criterion (AIC) and C-index were compared among scoring systems.RESULTSThe cohort included 1102 patients, mostly men, median age 68 [60-74] years with cirrhosis (81%), child-Pugh A (73%), alcohol-related (41%), HCV-related (27%). HCC were multinodular (59%) and vascular invasion was present in 41% of cases. At time of HCC diagnosis BCLC stages were A (17%), B (16%), C (60%) and D (7%). First line HCC treatment was curative in 23.5%, palliative in 59.5%, BSC in 17% of our population. Median OS was 10.8 mo [4.9-28.0]. Each system distinguished different survival prognosis groups (P < 0.0001). The nomogram had the highest discriminatory ability, the highest C-index value. NIACE score had the lowest AIC value. The nomogram distinguished sixteen different prognosis groups. By classifying unifocal large HCC into tumor burden 1, the nomogram was less powerful.CONCLUSIONIn this French cohort, the BCLC nomogram and the NIACE score provided the best prognostic information, but the NIACE could even help treatment strategies.

<p>Development and external validation of prognostic nomograms in hepatocellular carcinoma patients: a population based study</p>

“…Interestingly, they focused on several current common staging systems and compared their prognostic prediction abilities. In particular, the authors reassigned detailed and accurate scores of risk factors in the BCLC staging system using the nomogram model, whereas our study mainly focused on mining and building a new prognostic staging system based on clinical factors from a worldwide cohort 33…”

Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma

“…Even though routine screening programs in patients with chronic liver disease often allow earlier identification of patients with HCC, the number of patients diagnosed in advanced tumor stages is still high in Western countries [60,61]. For these patients, sorafenib was the only approved treatment for almost a decade until the recent approval of the multi-tyrosine kinase inhibitor regorafenib as second-line therapy [62].…”

Short‐ and long‐term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma

“…Unlike in other tumor entities, prognosis in HCC is determined not only by cancer biology, 4,5 but also by the severity of underlying liver disease, 6,7 and thus, both factors have to be considered for treatment selection. 8 While surgical and local ablative treatments are available for early stages of HCC, transarterial chemoembolization (TACE) represents the treatment of choice in patients with intermediate-stage HCC 9 and may also be considered in selected patients with unresectable early-stage HCC. 10 Intermediate-stage HCC patients are defined to be asymptomatic with liver-limited, multinodular, unresectable tumors and well-preserved liver function.…”